The drug, orforglipron, won a fast-track review voucher from the U.S. Food and Drug Administration that could cut review ...

Eli Lilly said on Monday it is confident about the supplies of its weight-loss pill orforglipron ahead of its anticipated U.S ...

Eli Lilly’s Mounjaro is the only dual drug on the market, targeting GLP-1 and GIP. Doctors say that Mounjaro is also more ...

Clinical trials show retatrutide, Eli Lilly's new triple-agonist drug, delivered 24.2% weight loss in 48 weeks and the ...

Humana’s CenterWell pharmacy will dispense GLP-1 weight loss drugs made by Eli Lilly as part of a new program for employers ...

Jan 8 () - Eli Lilly said on Thursday a late-stage trial showed its weight-loss drug Zepbound, used with ​its psoriatic ...

US at a fraction of the cost of injectable versions – has rather stolen their thunder. Patients used to paying more than ...

Combination therapy with ixekizumab and tirzepatide bested monotherapy with ixekizumab alone in both psoriatic arthritis and ...

Eli Lilly stock prepares €15B Abivax acquisition as tirzepatide revenue hits $24.8B. Orforglipron oral weight loss drug ...

Its lineup and pipeline put it well ahead of even its closest competitor. The drugmaker should continue riding this wave for the foreseeable future. Over the past few years, Eli Lilly (NYSE: LLY) has ...

People who stop taking weight-loss jabs such as Wegovy regain pounds much faster than those who halt exercising and dieting, ...

An approval of Lilly's pill, along with its current strength in the weight loss market, could equal revenue growth well into ...